October 23, 2025

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. **(NASDAQ: IBIO),** an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston.

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Monday, November 10, 2025, at 8:30 a.m. ET to discuss the Company's continued development in becoming a clinical-stage biotechnology company and to highlight its progress across iBio's next-generation obesity pipeline. Dr. Brenner will also outline how the Company's differentiated antibody programs are designed to complement existing obesity therapies and create long-term value through innovation and scientific leadership.

Felipe Duran, iBio's Chief Financial Officer, will be available with Dr. Brenner for one-on-one meetings during the conference.

A livestream of the event can be accessed here. A link to access the replay will be posted on the Investor section of the iBio website.

About iBio, Inc.

iBio (Nasdaq: **IBIO**) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company's continued development in becoming a clinical-stage biotechnology company; its progress across its next generation obesity pipeline; the Company's differentiated antibody programs complementing existing obesity therapies and creating long-term value through innovation and scientific leadership and the Company's; participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston ;. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to commence clinical trials; the ability of the Company's antibody programs to complement existing obesity therapies and create long-term value through innovation and scientific leadership; Activin E being a successful target for cardiometabolic disorders and obesity and iBio's antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com

Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

Source: iBio, Inc.